skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8847

Blood pressure goal achievement with olmesartan medoxomil-based treatment: additional analysis of the OLMEBEST study

Original Research

(3430) Views  (960) Full article downloads

Authors: Vivencio Barrios, Carlos Escobar, Alberto Calderon, et al

Published Date August 2009 Volume 2009:5 Pages 723 - 729
DOI: http://dx.doi.org/10.2147/VHRM.S7003

Vivencio Barrios1, Carlos Escobar1, Alberto Calderon2, Michael Böhm3

1Department of Cardiology, Hospital Ramón y Cajal, Madrid, Spain; 2Primary Care Center Rosa de Luxemburgo, Madrid, Spain; 3Klinik für Innere Medizin III, Universitätsklinikum des Saarlandes, Homburg/Saar, Germany

Aims: Guidelines recommend blood pressure (BP) in hypertensive patients should be <140 systolic BP (SBP) and <90 diastolic BP (DBP) mmHg. This analysis assessed goal rate achievement in hypertensive patients receiving olmesartan-based treatment in the OLMEBEST study.

Methods: Patients with essential hypertension (DBP ≥ 90 mmHg and <110 mmHg) received open-label olmesartan medoxomil 20 mg/day (n = 2306). After 8 weeks, patients with DBP ≥ 90 mmHg (n = 627) were randomized to 4 weeks’ double-blind treatment with olmesartan 40 mg/day monotherapy or olmesartan 20 mg/day plus hydrochlorothiazide (HCTZ) 12.5 mg/day. For this analysis, the numbers and proportions of patients who achieved SBP < 140 mmHg and/or DBP < 90 mmHg at the end of the 4 weeks were calculated.

Results: In patients who achieved DBP normalization (<90 mmHg) at week 8 (n = 1546) and continued open-label olmesartan 20 mg/day, 66.7% achieved SBP/DBP < 140/90 mmHg at Week 12. In patients who did not achieve DBP normalization at Week 8, 26.8% of those randomized to olmesartan 40 mg/day and 42.5% of those randomized to olmesartan 20 mg/day plus HCTZ 12.5 mg/day achieved a SBP/DBP < 140/90 mmHg at Week 12.

Conclusion: Olmesartan 40 mg/day and olmesartan 20 mg/day plus HCTZ 12.5 mg/day allow substantial proportions of patients to achieve BP goals.

Keywords: olmesartan medoxomil, hypertension, angiotensin II receptor blocker, goal rates, hydrochlorothiazide






 

Other articles by Dr Vivencio Barrios



Readers of this article also read:

Effect of angiotensin receptor blockade on endothelial function: focus on olmesartan medoxomil
Safety and efficacy of rosiglitazone in the elderly diabetic patient
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Effects of efforts to intensify management on blood pressure control among patients with type 2 diabetes mellitus and hypertension: A pilot study
Berberine: metabolic and cardiovascular effects in preclinical and clinical trials
Natriuretic peptides (BNP and NT-proBNP): measurement and relevance in heart failure
Cardiac risk stratification: Role of the coronary calcium score
ABO and rhesus blood group distribution in Kurds
Effectiveness and tolerability of a fixed-dose combination of olmesartan and amlodipine in clinical practice
Cardiac ryanodine receptor in metabolic syndrome: is JTV519 (K201) future therapy?
  • Join ISVH

    Be part of the World's leading experts in vascular health by joining the International Society of Vascular Health (ISVH)

  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University